[Association of polymorphisms in testosterone 5-alpha-reductase II genotype and prognosis factors of prostate cancer].
OBJECTIVE
The correlation were studied between testosterone 5-alpha-reductase II (SRD5A2) gene polymorphisms and prognosis factors.


METHODS
V89L and A49T variants was identified with Mwo1 and Rsa1. The differences of V89L and A49T between cancer of prostate (CaP) and benign prostatic hyperplasia (BPH) were studied. In addition, we also researched the association of polymorphisms with age of onset, free prostate specific antigen (FPSA), total PSA (TPSA), FPSA/TPSA (F/T), Gleason score, and T stage in cancer group.


RESULTS
We found no differences of V89L and A49T polymorphisms between CaP and BPH. In CaP group the A49T variant was associated with lower age of onset (P = 0.03) and higher Gleason score (P = 0.015). There were no differences between VV and VL+LL polymorphisms with any of the characteristics studied. When the characteristics above were regarded as two-level discrete variable, there were no differences by A49T and V89Lvariants.


CONCLUSIONS
In CaP group, the AT+TT genotype was perhaps associated with poor prognosis. VL+LL genotype has no relation with prognosis.
Tong
Ming
M
Institute of Urology, First Hospital, Peking University, Beijing 100034, China.
Xu
Zhong
Z
Ai
Jun-kui
JK
Yuan
Yi-ming
YM
Yin
Yi
Y
Wang
Jun-qi
JQ
Li
Hong-wei
HW
Liu
Jian-he
JH
Xin
Dian-qi
DQ
Zhou
Li-qun
LQ
Li
Ming
M
Na
Yan-qun
YQ
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000235:genetics*; D000368:Aged; D000369:Aged, 80 and over; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000235:genetics; D011471:Prostatic Neoplasms / Q000097:blood / Q000235:genetics* / Q000473:pathology
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D017430:Prostate-Specific Antigen